N-acetylcysteine and metabotropic glutamate receptors: Implications for the treatment of schizophrenia: A literature review

Psychiatric Quarterly

Volumn 85, Issue 2, 2014, Pages 177-185

  Zavodnick, Adam Daniel ^a   Ali, Rizwan ^b  

^a VIRGINIA TECH CARILION SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Metabotropic glutamate receptor; mglu; N Acetylcysteine; Schizophrenia

Indexed keywords

ACETYLCYSTEINE; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; IONOTROPIC RECEPTOR;

ARTICLE; GLIA CELL; HUMAN; NEUROTRANSMISSION; NONHUMAN; SCHIZOPHRENIA; SYSTEMATIC REVIEW; AGONISTS; CLASSIFICATION; METABOLISM; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ACETYLCYSTEINE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, IONOTROPIC GLUTAMATE; RECEPTORS, METABOTROPIC GLUTAMATE; SCHIZOPHRENIA;

EID: 84899992443     PISSN: 00332720     EISSN: 15736709     Source Type: Journal    
DOI: 10.1007/s11126-013-9281-3     Document Type: Article

References (28)

1. Moghaddam B, Javitt D: From revolution to evolution: The glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 37(1):4-15, 2012.
2. Coyle J, Leski M, Morrison J, et al.: The diverse roles of L-glutamic acid in brain signal transduction. In: Davis K, Charney D, Coyle J, Nemeroff C (Eds) Neuropsychopharmacology (The Fifth Generation of Progress). Philadelphia: Lippincott, Williams & Wilkins, pp. 71-90, 2002.
3. Adell A, Jiménez-Sánchez L, López-Gil X, Romón T: Is the acute NMDA receptor hypofunction a valid model of schizophrenia? Schizophrenia Bulletin 38(1):9-14, 2012.
4. Goff DC, Coyle JT: The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. American Journal of Psychiatry 158(9):1367-1377, 2001. (Pubitemid 32847232)
5. Sansone RA, Sansone LA: Getting a knack for NAC: N-acetyl-cysteine. Innovations in Clinical Neuroscience 8(1):10-14, 2011.
6. Dean O, Giorlando F, Berk M: N-acetylcysteine in psychiatry: Current therapeutic evidence and potential mechanisms of action. Journal of Psychiatry & Neuroscience 36(2):78-86, 2011.
7. Bridges R, Lutgen V, Lobner D, Baker DA: Thinking outside the cleft to understand synaptic activity: Contribution of the cystine-glutamate antiporter (System xc-) to normal and pathological glutamatergic signaling. Pharmacological Reviews 64(3):780-802, 2012.
8. Sathyasaikumar KV, Stachowski EK, Wonodi I, Roberts RC, Rassoulpour A, McMahon RP, Schwarcz R: Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophrenia Bulletin 37(6):1147-1156, 2011.
9. Olive MF, Cleva RM, Kalivas PW, Malcolm RJ: Glutamatergic medications for the treatment of drug and behavioral addictions. Pharmacology Biochemistry and Behavior 100(4):801-810, 2012.
10. Stefani MR, Moghaddam B: Activation of type 5 metabotropic glutamate receptors attenuates deficits in cognitive flexibility induced by NMDA receptor blockade. European Journal of Pharmacology 639(1-3):26-32, 2010.
11. Marek GJ: Metabotropic glutamate2/3 (mGlu2/3) receptors, schizophrenia and cognition. European Journal of Pharmacology 639(1-3):81-90, 2010.
12. Chaki S: Group II metabotropic glutamate receptor agonists as a potential drug for schizophrenia. European Journal of Pharmacology 639(1-3):59-66, 2010.
13. O'Connor RM, Finger BC, Flor PJ, Cryan JF: Metabotropic glutamate receptor 7: At the interface of cognition and emotion. European Journal of Pharmacology 639(1-3):123-131, 2010.
14. Moran MM, McFarland K, Melendez RI, Kalivas PW, Seamans JK: Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. The Journal of Neuroscience 25(27):6389-6393.
15. Wolf JA, Moyer JT, Lazarewicz MT, Contreras D, Benoit-Marand M, O'Donnell P, Finkel LH: NMDA/AMPA ratio impacts state transitions and entrainment to oscillations in a computational model of the nucleus accumbens medium spiny projection neuron. The Journal of Neuroscience 25(40):9080-9095, 2005. (Pubitemid 41509041)
16. Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH: Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). The New England Journal of Medicine 319(24):1557-1562, 1988. (Pubitemid 19003420)
17. Nguyen-Khac E, Thevenot T, Piquet MA, Benferhat S, Goria O, Chatelain D, Tramier B, Dewaele F, Ghrib S, Rudler M, Carbonell N, Tossou H, Bental A, Bernard-Chabert B, Dupas JL; AAH-NAC Study Group: Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. The New England Journal of Medicine 365(19):1781-1789, 2011.
18. Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, De Metrio M, Galli S, Fabbiocchi F, Montorsi P, Veglia F, Bartorelli AL: N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. The New England Journal of Medicine 354(26):2773-2782, 2006. (Pubitemid 43974195)
19. Bošković M, Vovk T, Kores Plesničar B, Grabnar I: Oxidative stress in schizophrenia. Current Neuropharmacology 9(2):301-312, 2011.
20. Gysin R, Kraftsik R, Sandell J, Bovet P, Chappuis C, Conus P, Deppen P, Preisig M, Ruiz V, Steullet P, Tosic M, Werge T, Cuénod M, Do KQ: Impaired glutathione synthesis in schizophrenia: Convergent genetic and functional evidence. Proceedings of the National Academy of Sciences of the United States of America 104(42):16621-16666, 2007.
21. Shungu DC: N-acetylcysteine for the treatment of glutathione deficiency and oxidative stress in schizophrenia. Biological Psychiatry 71(11):937-938, 2012.
22. Baker DA, Madayag A, Kristiansen LV, Meador-Woodruff JH, Haroutunian V, Raju I: Contribution of cystine-glutamate antiporters to the psychotomimetic effects of phencyclidine. Neuropsychopharmacology 33(7):1760-1772, 2008. (Pubitemid 351684701)
23. Fukami G, Hashimoto K, Koike K, Okamura N, Shimizu E, Iyo M: Effect of antioxidant N-acetyl-L-cysteine on behavioral changes and neurotoxicity in rats after administration of methamphetamine. Brain Research 1016(1):90-95, 2004. (Pubitemid 38834276)
24. Bulut M, Savas HA, Altindag A, Virit O, Dalkilic A: Beneficial effects of N-acetylcysteine in treatment resistant schizophrenia. The World Journal of Biological Psychiatry 10(4 Pt 2):626-628, 2009.
25. Lavoie S, Murray MM, Deppen P, Knyazeva MG, Berk M, Boulat O, Bovet P, Bush AI, Conus P, Copolov D, Fornari E, Meuli R, Solida A, Vianin P, Cuénod M, Buclin T, Do KQ: Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 33(9):2187-2199, 2008. (Pubitemid 351992093)
26. Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Judd F, Katz F, Katz P, Ording-Jespersen S, Little J, Conus P, Cuenod M, Do KQ, Bush AI: N-acetyl cysteine as a glutathione precursor for schizophrenia: A double-blind, randomized, placebo-controlled trial. Biological Psychiatry 64(5):361-368, 2008.
27. Gunduz-Bruce H, Reinhart RM, Roach BJ, Gueorguieva R, Oliver S, D'Souza DC, Ford JM, Krystal JH, Mathalon DH: Glutamatergic modulation of auditory information processing in the human brain. Biological Psychiatry 71(11):969-977, 2012.
28. Berk M, Dean O, Cotton SM, Gama CS, Kapczinski F, Fernandes BS, Kohlmann K, Jeavons S, Hewitt K, Allwang C, Cobb H, Bush AI, Schapkaitz I, Dodd S, Malhi GS: The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: An open label trial. Journal of Affective Disorders 135(1-3):389-394, 2011.